- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05271175
Accelerated iTBS in Smoking Cessation
Accelerated Intermittent Theta Burst Stimulation in Smoking Cessation: A Randomized Controlled Study
Cigarette smoking is one of the foremost causes of preventable disease and premature death. In 2014, 68% of adult smokers wanted to quit smoking and in 2017, 55.1% of adult smokers had made a quit attempt. However, only a small percentage of adult smokers (7,4%) achieved to quit smoking.
Transcranial magnetic stimulation (TMS) is a novel, powerful, non-invasive brain stimulation therapy. This study used Theta Burst Stimulation (TBS), a newer form of rTMS protocol that can be delivered in a shorter duration compared to the standard rTMS protocol, while delivering a comparable number of pulses. It is a tolerable, powerful, and useful tool in non-invasive brain stimulation therapies.
This double-blind randomized control trial evaluated the efficacy of 4 iTBS sessions per day during 5 consecutive days over the left DLPFC in smoking cessation. Moreover, it investigated whether the exposure to smoking-related cues during the rTMS treatment, compared to neutral cues impact cigarette craving.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cigarette smoking is one of the foremost causes of preventable disease and premature death. In 2014, 68% of adult smokers wanted to quit smoking and in 2017, 55.1% of adult smokers had made a quit attempt. However, only a small percentage of adult smokers (7,4%) achieved to quit smoking. Behavioral and psychological interventions, pharmacological interventions as well as nicotine replacement therapy are some of the most used interventions for smoking cessation with medium to low success rates. Nonetheless, in recent years there has been growing interest in new, alternative, and effective treatments for smoking cessation.
Transcranial magnetic stimulation (TMS) is a novel, powerful, non-invasive brain stimulation therapy. TMS non-invasively (transcranially) delivers magnetic pulses to a brain region, inducing electric a current that can depolarize neurons and induce action potentials. This study used Theta Burst Stimulation (TBS), a newer form of rTMS protocol that can be delivered in a shorter duration compared to the standard rTMS protocol, while delivering a comparable number of pulses. It is a tolerable, powerful, and useful tool in non-invasive brain stimulation therapies.
This double-blind randomized control trial evaluated the efficacy of 4 iTBS sessions per day during 5 consecutive days over the left DLPFC in smoking cessation. Moreover, it investigated whether the exposure to smoking-related cues during the rTMS treatment, compared to neutral cues impact cigarette craving. The investigators hypothesized that twenty sessions of accelerated theta burst simulation over the left DLPFC while exposed to smoking-related cues, would reduce cigarette consumption and cigarette cravings, accompanied by reduced stress and motivation to quit smoking, compared to both active and sham stimulation with neutral-cues.
A total of 104 cigarettes smokers, who wanted to quit smoking, were enrolled and were randomly divided into the three experimental groups: the first group received active aiTBS stimulation while watching neutral videos, the second group received active aiTBS stimulation while watching smoking-related videos and the last group received sham stimulation while watching smoking-related videos. Primary and secondary measurements were performed at the baseline, during the treatment period, at one week, one month and six months post rTMS treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Larnaca, Cyprus
- Cyprus rTMS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 18-70
- native or fluent Greek speaker.
Exclusion Criteria:
- mental objects or implants in the brain, skull or near head (e.g., pacemakers, metal plates)
- past or current of diagnosis of neurological or psychiatric disorder
- use of psychiatric medication
- past or current drug or alcohol abuse, other than nicotine
- use of IQOS ("I Quit Original Smoking") or electronic cigarettes (e-cigarettes).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active TMS & Neutral videos
Received active iTBS stimulation while watching neutral videos
|
An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
|
Experimental: Active TMS & Smoking videos
Received active iTBS stimulation while watching smoking-related videos
|
An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
|
Sham Comparator: Sham TMS & Smoking videos
Received sham stimulation while watching smoking-related videos
|
An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true "double blinded" clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported Nicotine Consumption
Time Frame: Baseline
|
Τhe number of cigarettes participants usually smoke before the treatment.
|
Baseline
|
Self-reported Nicotine Consumption
Time Frame: After 1st treatment day
|
Participants were required to record the number of cigarettes smoked after the completion of the 1st day of treatment until before the first session on the second day of treatment.
Participants were asked not to smoke during the breaks of the 4 daily rTMS sessions
|
After 1st treatment day
|
Self-reported Nicotine Consumption
Time Frame: After 2nd treatment day
|
Participants were required to record the number of cigarettes smoked after the completion of the 2nd day of treatment until before the first session on the 3rd day of treatment.
Participants were asked not to smoke during the breaks of the 4 daily rTMS sessions
|
After 2nd treatment day
|
Self-reported Nicotine Consumption
Time Frame: After 3rd treatment day
|
Participants were required to record the number of cigarettes smoked after the completion of the 3rd day of treatment until before the first session on the 4th day of treatment.
Participants were asked not to smoke during the breaks of the 4 daily rTMS sessions
|
After 3rd treatment day
|
Self-reported Nicotine Consumption
Time Frame: After 4th treatment day
|
Participants were required to record the number of cigarettes smoked after the completion of the 4th day of treatment until before the first session on the 5th day of treatment .
Participants were asked not to smoke during the breaks of the 4 daily rTMS sessions
|
After 4th treatment day
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Baseline
|
CO level was measured using the piCO Smokerlyzer breath carbon monoxide meter device prior to the first rTMS session.
|
Baseline
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Day 1
|
The average of the four CO-levels, measured before each of the four sessions on Day 1.
|
Day 1
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Day 2
|
The average of the four CO-levels, measured before each of the four sessions on Day 2.
|
Day 2
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Day 3
|
The average of the four CO-levels, measured before each of the four sessions on Day 3.
|
Day 3
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Day 4
|
The average of the four CO-levels, measured before each of the four sessions on Day 4.
|
Day 4
|
Carbon Monoxide (CO)- Evaluated Nicotine Consumption
Time Frame: Day 5
|
The average of the four CO-levels, measured before each of the four sessions on Day 5.
|
Day 5
|
Nicotine Dependence
Time Frame: Baseline
|
Fagerström test for Nicotine Dependence (FTND) is a short, self-report measure that assesses nicotine dependence.
It contains six questions, and the total score is calculated as a sum of these six questions.
The scores vary from 0 to 10, with lower scores indicating lower dependence on nicotine.
|
Baseline
|
Nicotine Dependence
Time Frame: End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Fagerström test for Nicotine Dependence (FTND) is a short, self-report measure that assesses nicotine dependence.
It contains six questions, and the total score is calculated as a sum of these six questions.
The scores vary from 0 to 10, with lower scores indicating lower dependence on nicotine.
|
End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Nicotine Dependence
Time Frame: 1 week follow up
|
Fagerström test for Nicotine Dependence (FTND) is a short, self-report measure that assesses nicotine dependence.
It contains six questions, and the total score is calculated as a sum of these six questions.
The scores vary from 0 to 10, with lower scores indicating lower dependence on nicotine.
|
1 week follow up
|
Nicotine Dependence
Time Frame: 1 month follow up
|
Fagerström test for Nicotine Dependence (FTND) is a short, self-report measure that assesses nicotine dependence.
It contains six questions, and the total score is calculated as a sum of these six questions.
The scores vary from 0 to 10, with lower scores indicating lower dependence on nicotine.
|
1 month follow up
|
Nicotine Dependence
Time Frame: 6 months follow up
|
Fagerström test for Nicotine Dependence (FTND) is a short, self-report measure that assesses nicotine dependence.
It contains six questions, and the total score is calculated as a sum of these six questions.
The scores vary from 0 to 10, with lower scores indicating lower dependence on nicotine.
|
6 months follow up
|
Momentary Craving
Time Frame: Baseline
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale.
The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS.
We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet.
|
Baseline
|
Momentary Craving
Time Frame: Day 1
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale. The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS. We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet. The average of the eight VAS scores, measured prior and post each of the four sessions on Day 1. |
Day 1
|
Momentary Craving
Time Frame: Day 2
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale. The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS. We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet. The average of the eight VAS scores, measured prior and post each of the four sessions on Day 2. |
Day 2
|
Momentary Craving
Time Frame: Day 3
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale. The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS. We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet. The average of the eight VAS scores, measured prior and post each of the four sessions on Day 3. |
Day 3
|
Momentary Craving
Time Frame: Day 4
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale. The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS. We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet. The average of the eight VAS scores, measured prior and post each of the four sessions on Day 4. |
Day 4
|
Momentary Craving
Time Frame: Day 5
|
The Visual Analogue Scale (VAS) is a psychometric measurement instrument that measures symptom severity on a continuous scale. The VAS can be quickly and repeatedly administered between tasks and it has been used extensively in smoking research with TMS. We used the VAS to assess smoking craving by asking participants to respond to the question "How much do you want to smoke right now?", on a scale from 0 "no craving" to 100 "most craving ever experienced" by choosing a response on a visual scale given in front of them on a tablet. The average of the eight VAS scores, measured prior and post each of the four sessions on Day 5. |
Day 5
|
General Craving
Time Frame: Baseline
|
Tobacco Craving Questionnaire-Short Form (TCQ-SF) is a self-report measure that assesses tobacco craving in four dimensions.
Each factor scale contains three items.
TCQ-SF items were rated on a Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total scores vary from 12 to 84, by summing the 12 items and the scores for each factor scale vary from 3 to 21 by summing the three items in each factor scale.
A high score indicates high tobacco craving.
|
Baseline
|
General Craving
Time Frame: End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Tobacco Craving Questionnaire-Short Form (TCQ-SF) is a self-report measure that assesses tobacco craving in four dimensions.
Each factor scale contains three items.
TCQ-SF items were rated on a Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total scores vary from 12 to 84, by summing the 12 items and the scores for each factor scale vary from 3 to 21 by summing the three items in each factor scale.
A high score indicates high tobacco craving.
|
End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
General Craving
Time Frame: 1 week follow up
|
Tobacco Craving Questionnaire-Short Form (TCQ-SF) is a self-report measure that assesses tobacco craving in four dimensions.
Each factor scale contains three items.
TCQ-SF items were rated on a Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total scores vary from 12 to 84, by summing the 12 items and the scores for each factor scale vary from 3 to 21 by summing the three items in each factor scale.
A high score indicates high tobacco craving.
|
1 week follow up
|
General Craving
Time Frame: 1 month follow up
|
Tobacco Craving Questionnaire-Short Form (TCQ-SF) is a self-report measure that assesses tobacco craving in four dimensions.
Each factor scale contains three items.
TCQ-SF items were rated on a Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total scores vary from 12 to 84, by summing the 12 items and the scores for each factor scale vary from 3 to 21 by summing the three items in each factor scale.
A high score indicates high tobacco craving.
|
1 month follow up
|
General Craving
Time Frame: 6 months follow up
|
Tobacco Craving Questionnaire-Short Form (TCQ-SF) is a self-report measure that assesses tobacco craving in four dimensions.
Each factor scale contains three items.
TCQ-SF items were rated on a Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total scores vary from 12 to 84, by summing the 12 items and the scores for each factor scale vary from 3 to 21 by summing the three items in each factor scale.
A high score indicates high tobacco craving.
|
6 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived Stress
Time Frame: Baseline
|
Perceived Stress Scale-4 (PSS-4) is a self-report measure that is used to assess psychological stress.
PSS-4 items were rated on a Likert scale, ranging from 0 to 4, with those on the positive subscale scored in reverse and the total score was calculated as a sum of these items.
The scores vary from 0-16, with a higher score indicating higher perceived stress.
|
Baseline
|
Perceived Stress
Time Frame: End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Perceived Stress Scale-4 (PSS-4) is a self-report measure that is used to assess psychological stress.
PSS-4 items were rated on a Likert scale, ranging from 0 to 4, with those on the positive subscale scored in reverse and the total score was calculated as a sum of these items.
The scores vary from 0-16, with a higher score indicating higher perceived stress.
|
End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Perceived Stress
Time Frame: 1 week follow up
|
Perceived Stress Scale-4 (PSS-4) is a self-report measure that is used to assess psychological stress.
PSS-4 items were rated on a Likert scale, ranging from 0 to 4, with those on the positive subscale scored in reverse and the total score was calculated as a sum of these items.
The scores vary from 0-16, with a higher score indicating higher perceived stress.
|
1 week follow up
|
Perceived Stress
Time Frame: 1 month follow up
|
Perceived Stress Scale-4 (PSS-4) is a self-report measure that is used to assess psychological stress.
PSS-4 items were rated on a Likert scale, ranging from 0 to 4, with those on the positive subscale scored in reverse and the total score was calculated as a sum of these items.
The scores vary from 0-16, with a higher score indicating higher perceived stress.
|
1 month follow up
|
Perceived Stress
Time Frame: 6 months follow up
|
Perceived Stress Scale-4 (PSS-4) is a self-report measure that is used to assess psychological stress.
PSS-4 items were rated on a Likert scale, ranging from 0 to 4, with those on the positive subscale scored in reverse and the total score was calculated as a sum of these items.
The scores vary from 0-16, with a higher score indicating higher perceived stress.
|
6 months follow up
|
Motivation to Quit Smoking
Time Frame: Baseline
|
Participants were asked to estimate how motivated they were to quit smoking from 0% to 100%.
Τhe possible answers were: 0%, 25%, 50%, 75% and 100%.
Higher values reflect greater motivation to quit smoking.
|
Baseline
|
Motivation to Quit Smoking
Time Frame: End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Participants were asked to estimate how motivated they were to quit smoking from 0% to 100%.
Τhe possible answers were: 0%, 25%, 50%, 75% and 100%.
Higher values reflect greater motivation to quit smoking.
|
End of the treatment (On the fifth day, after completing 20 TMS sessions)
|
Motivation to Quit Smoking
Time Frame: 1 week follow up
|
Participants were asked to estimate how motivated they were to quit smoking from 0% to 100%.
Τhe possible answers were: 0%, 25%, 50%, 75% and 100%.
Higher values reflect greater motivation to quit smoking.
|
1 week follow up
|
Motivation to Quit Smoking
Time Frame: 1 month follow up
|
Participants were asked to estimate how motivated they were to quit smoking from 0% to 100%.
Τhe possible answers were: 0%, 25%, 50%, 75% and 100%.
Higher values reflect greater motivation to quit smoking.
|
1 month follow up
|
Motivation to Quit Smoking
Time Frame: 6 months follow up
|
Participants were asked to estimate how motivated they were to quit smoking from 0% to 100%.
Τhe possible answers were: 0%, 25%, 50%, 75% and 100%.
Higher values reflect greater motivation to quit smoking.
|
6 months follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Sack, Maastricht University, The Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08.2019CY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Active intermittent theta burst stimulation
-
Changping LaboratoryNot yet recruitingAphasia | Stroke, Ischemic
-
Bradley HospitalRecruitingWorking MemoryUnited States
-
Fabio FerrarelliNational Institute of Mental Health (NIMH)RecruitingSchizophreniaUnited States
-
University of Sao Paulo General HospitalRecruitingParkinson Disease | Gait Disorders, NeurologicBrazil
-
Hôpital le VinatierTerminated
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Nicholas Balderston, PhDRecruiting
-
Sunnybrook Health Sciences CentreRecruitingPost Concussion SyndromeCanada
-
King's College LondonSouth London and Maudsley NHS Foundation TrustWithdrawnBinge-Eating DisorderUnited Kingdom
-
Erika ForbesNational Institute of Mental Health (NIMH)Completed